 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- NEXI-002 / NexImmune
Trial completion date, Trial primary completion date: Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 16, 2024
P1/2, N=9, Suspended, Sponsor: NexImmune Inc.
Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Nov 2023 --> Nov 2024
- NEXI-002 / NexImmune
Trial completion date, Trial suspension, Trial primary completion date: Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 14, 2022
P1/2, N=9, Suspended, Sponsor: NexImmune Inc.
Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Nov 2023 --> Nov 2024 Trial completion date: Nov 2022 --> Dec 2023 | Terminated --> Suspended | Trial primary completion date: Aug 2022 --> Nov 2023
- | NEXI-002 / NexImmune
Enrollment change, Trial termination: Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 22, 2022
P1/2, N=9, Terminated, Sponsor: NexImmune Inc.
Trial completion date: Nov 2022 --> Dec 2023 | Terminated --> Suspended | Trial primary completion date: Aug 2022 --> Nov 2023 N=22 --> 9 | Recruiting --> Terminated; Lack of accrual
- NEXI-002 / NexImmune
Phase 1/2 Study of Nexi-002 Autologous Multi-Antigen-Specific CD8+ T Cells for the Treatment of Relapsed or Refractory Multiple Myeloma (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_4469;
RNA Seq transcriptional profiling of the CD8+ T cells is planned. Additional patients have recently received NEXI-002 infusions and the trial will continue to be expanded to gain additional safety, immunologic, and clinical activity experience.
- NEXI-002 / NexImmune
In vivo and in vitro characterization of AIM ACT, a novel nanoparticle-based technology, expanded MART-1 specific T cells (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_858;
P1/2
The AIM ACT platform is currently being used for generating T cell products for our current clinical trials, NEXI-001 (NCT04284228) and NEXI-002 (NCT04505813), and our pre-clinical development for HPV-associated malignancies. The findings support initiating Phase I trials of adoptive T cell therapy in solid tumors.
- NEXI-002 / NexImmune, Zarzio (filgrastim biosimilar) / Novartis
[VIRTUAL] PRELIMINARY ANALYSIS OF A PHASE 1 STUDY OF NEXI-002 AUTOLOGOUS MULTI-AGENT-SPECIFIC CD8+ T CELLS FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) () - May 13, 2021 - Abstract #EHA2021EHA_1405;
Results Three patients were treated with single infusions of 80 to 100 million cells of NEXI-002 following lymphodepleting chemotherapy (fludarabine 30 mg/m2 and cyclophosphamide 300 mg/m2 on Days -5 to -3)...Due to these encouraging findings, the trial will be expanded to gain greater safety and activity experience with NEXI-002. Updated data will be available.
- || NEXI-002 / NexImmune
New P1/2 trial: Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 9, 2020
P1/2, N=22, Recruiting, Sponsor: NexImmune Inc.